15,048 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, HoldingsChannel reports. The firm acquired 15,048 shares of the company’s stock, valued at approximately $332,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $44,000. Ameliora Wealth Management Ltd. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth about $66,000. IFP Advisors Inc increased its position in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after purchasing an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its position in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock worth $96,000 after purchasing an additional 949 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on TEVA. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Wednesday, April 23rd. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Finally, JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and a consensus price target of $24.43.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.95 on Friday. The firm has a market capitalization of $19.22 billion, a P/E ratio of -11.69, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business’s 50-day simple moving average is $15.35 and its 200-day simple moving average is $17.41.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.48 EPS. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.